PatternsRadar
Sign in

SUPRIYASupriya Lifescience Limited

NSE
Full chart
915.35INR+15.80 (+1.76%)Close · 6 Oct 2026
13 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹7,367 CrMarket cap
37.1P/E (TTM)
39.7%Delivery

Filings & corporate actions

19 results filed
CSV
Next results · Q2 FY27
Expected 28 Oct 2026 – 12 Nov 2026
Estimate: filed 28–43 days after quarter end, last 4 times
Dividend
₹1.00 per share · last 4 Sept 2026
2026
  • 4 SeptdividendDividend · ₹1.00 per share+1.2%
  • 13 AugresultsResults · Q1 FY27 · standalone-2.7%NSE
  • 18 JulshareholdingShareholding · 30 Jun 2026+1.0%NSE
  • 27 MayresultsResults · Q4 FY26 · standalone+20.0%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026+1.6%NSE
  • 9 FebresultsResults · Q3 FY26 · standalone-0.1%NSE
  • 20 JanshareholdingShareholding · 31 Dec 2025-2.2%NSE

Reaction to results · all yearsrose on day 0 in 6 of 19 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2713 Aug 2026-2.7%-1.0%+10.8%6.6×
Q4 FY2627 May 2026+20.0%+17.4%+20.3%24.9×
Q3 FY269 Feb 2026-0.1%-2.7%-13.3%2.3×
Q2 FY2612 Nov 2025+3.2%+1.4%-2.0%4.1×
Q1 FY2613 Aug 2025-0.9%+5.1%-1.8%4.4×
Q4 FY2527 May 2025-1.0%-4.1%-8.1%2.3×
Q3 FY2524 Jan 2025-5.3%+2.9%-8.7%1.9×
Q2 FY2528 Oct 2024+8.8%+16.4%+36.6%4.6×
Q1 FY2510 Aug 2024+13.9%+19.0%+35.6%16.9×
Q4 FY2429 May 2024-4.2%-4.2%+6.2%3.3×
Q3 FY248 Feb 2024+13.0%+19.6%+13.5%23.2×
Q2 FY248 Nov 2023-5.1%-3.0%+7.2%2.7×
Q1 FY244 Aug 2023-0.2%-4.8%-0.8%2.1×
Q4 FY2327 May 2023-1.9%-1.5%-3.2%0.5×
Q3 FY2315 Feb 2023-2.8%+5.5%-1.1%8.2×
Q2 FY2311 Nov 2022-2.8%-2.6%-4.1%2.2×
Q1 FY2313 Aug 2022+2.1%+0.5%-1.5%2.5×
Q4 FY2221 May 2022-3.3%-4.7%-21.1%1.1×
Q3 FY2221 Jan 2022-1.3%-1.5%-18.2%—
Average+1.6%+3.0%+2.4%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+30.8%
Profit YoY-30.9%
Interest cost YoY-6.0%
Revenue QoQ-31.4%
Profit QoQ-67.6%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+20.7%+21.1%————
Profit+21.1%+28.7%————

Key data

CSV
Open900.00
Day range885.00 – 917.40
52-week range545.50 – 1,085.00
From 52w high-15.6%
RSI (14)50.6
ATR (14)41.39
Volume1.77L
Avg volume (20D)3.58L
Rel volume0.49×
Volatility (1Y)47.5%
Turnover₹16.2Cr
SMA 50 / 200873.45 / 775.14

Delivery percentage

Latest · 6 Oct 202639.7%
20-day avg39.5%
1-year avg46.4%
Percentile (own history)32nd
Range10.9–80.4%
Sessions1,180

Over the last 20 sessions SUPRIYA settled 39.5% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 46.4%, so recent sessions are running 6.9 points lower than usual. The latest session ranks higher than 32% of the 1,180 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.76%-7.05%+8.62%+8.66%+49.52%+30.39%

Valuation

CSV
Market cap₹7,367 Cr
P/E (TTM)37.1
EPS (TTM)24.65
Shares outstanding8.05Cr
Listed28 Dec 2021

Ownership

CSV
Promoter68.30%
Promoter Δ QoQ0.00 pp
Public31.70%
FII6.19%
DII5.30%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)199.8206.4276.5189.7
YoY chg+20.3%+11.2%+50.2%+30.8%
Net profit (₹ Cr)50.449.774.224.0
YoY chg+9.3%+6.2%+47.3%-30.9%
Net margin25.2%24.1%26.8%12.7%
EPS6.276.179.222.99

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 68.30% · public 31.70%
23 Dec 2021: promoter 68.24%31 Dec 2021: promoter 68.24%31 Mar 2022: promoter 68.24%30 Jun 2022: promoter 68.24%30 Sept 2022: promoter 68.24%31 Dec 2022: promoter 68.24%31 Mar 2023: promoter 68.28%30 Jun 2023: promoter 68.30%30 Sept 2023: promoter 68.30%31 Dec 2023: promoter 68.30%31 Mar 2024: promoter 68.30%30 Jun 2024: promoter 68.30%30 Sept 2024: promoter 68.30%31 Dec 2024: promoter 68.30%31 Mar 2025: promoter 68.30%30 Jun 2025: promoter 68.30%30 Sept 2025: promoter 68.30%31 Dec 2025: promoter 68.30%31 Mar 2026: promoter 68.30%30 Jun 2026: promoter 68.30%
2021-122026-06
  • Promoter
  • Public and others
Promoter
68.30%
Public
31.70%
Promoter change
0.00 pp
Filed
18 Jul 2026
FII
6.19%
DII
5.30%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations140.1140.1158.2160.6166.1185.6184.1145.1199.8206.4276.5189.7
Other income2.53.12.22.22.52.13.02.72.72.63.52.6
Total income142.6143.1160.4162.9168.6187.7187.1147.7202.6209.1280.0192.4
Total expenses112.8103.0107.2103.1106.6125.2123.0100.3134.2141.7187.9151.6
└ Finance costs0.50.50.60.30.40.50.40.50.40.50.50.4
└ Depreciation4.04.03.94.74.75.06.16.56.66.88.58.9
Profit before tax29.840.153.259.862.162.664.147.468.366.992.140.8
Tax expense5.910.316.215.115.915.813.712.617.917.217.916.7
Net profit23.929.836.944.646.146.850.434.850.449.774.224.0
EPS2.973.704.595.545.715.826.294.326.276.179.222.99
Net margin17.05%21.27%23.35%27.79%27.78%25.20%27.37%23.98%25.23%24.06%26.84%12.67%
PBT margin21.26%28.63%33.62%37.21%37.36%33.71%34.80%32.68%34.19%32.42%33.32%21.50%
Tax rate19.79%25.72%30.55%25.31%25.64%25.24%21.35%26.62%26.19%25.77%19.43%41.06%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 13 Aug 2026.

SUPRIYA at a glance

  • SUPRIYA closed at ₹915.35 on 6 Oct 2026, +1.76% on the day, +30.4% over one year, 15.6% below its 52-week high of ₹1,085.
  • Delivery was 39.7% of traded quantity on 6 Oct 2026, the 32nd percentile of its own 1,180 sessions with a reading (20-session average 39.5%, 1-year average 46.4%).
  • Market capitalisation is ₹7,367 crore at a trailing P/E of 37.1 (trailing EPS ₹24.65).
  • Q1 FY27 results (standalone, filed 13 Aug 2026): revenue ₹190 crore (+30.8% year on year), net profit ₹24 crore (-30.9%); the price moved -2.7% on the first session after.
  • Promoters held 68.30% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 28 Oct 2026 and 12 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE07RO01027
SeriesEQ
Listed28 Dec 2021
History from28 Dec 2021
Sessions1,183
Turnover rank#591

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE